key: cord-0326904-ywr6s9a1
authors: Schult, David; Reitmeier, Sandra; Koyumdzhieva, Plamena; Lahmer, Tobias; Middelhoff, Moritz; Erber, Johanna; Schneider, Jochen; Kager, Juliane; Frolova, Marina; Horstmann, Julia; Fricke, Lisa; Steiger, Katja; Jesinghaus, Moritz; Janssen, Klaus-Peter; Protzer, Ulrike; Neuhaus, Klaus; Schmid, Roland M.; Haller, Dirk; Quante, Michael
title: Gut Bacterial Dysbiosis and Instability is Associated with the Onset of Complications and Mortality in COVID-19
date: 2021-10-09
journal: bioRxiv
DOI: 10.1101/2021.10.08.463613
sha: c66c821eff26a10d09b1fd29ddd8e180d104c754
doc_id: 326904
cord_uid: ywr6s9a1

Objective There is a growing debate about the involvement of the gut microbiome in COVID-19, although it is not conclusively understood whether the microbiome has an impact on COVID-19, or vice versa, especially as analysis of amplicon data in hospitalized patients requires sophisticated cohort recruitment and integration of clinical parameters. Here, we analyzed fecal and saliva samples from SARS-CoV-2 infected and post COVID-19 patients and controls considering multiple influencing factors during hospitalization. Design 16S rRNA gene sequencing was performed on fecal and saliva samples from 108 COVID-19 and 22 post COVID-19 patients, 20 pneumonia controls and 26 asymptomatic controls. Patients were recruited over the first and second corona wave in Germany and detailed clinical parameters were considered. Serial samples per individual allowed intra-individual analysis. Results We found the gut and oral microbiota to be altered depending on number and type of COVID-19-associated complications and disease severity. The occurrence of individual complications was correlated with low-risk (e.g., Faecalibacterium prausznitzii) and high-risk bacteria (e.g., Parabacteroides). We demonstrated that a stable gut bacterial composition was associated with a favorable disease progression. Based on gut microbial profiles, we identified a model to estimate mortality in COVID-19. Conclusion Gut microbiota are associated with the occurrence of complications in COVID-19 and may thereby influencing disease severity. A stable gut microbial composition may contribute to a favorable disease progression and using bacterial signatures to estimate mortality could contribute to diagnostic approaches. Importantly, we highlight challenges in the analysis of microbial data in the context of hospitalization.

The global pandemic caused by the new severe acute respiratory syndrome coronavirus 2 56 (SARS-CoV-2) brought the health systems to its limitations. The disease is characterized by 57 respiratory symptoms although there is increasing evidence of gastrointestinal (GI) tract 58 involvement[1, 2, 3]. At 15-39%, nausea, vomiting, and diarrhea are relatively common in 59 COVID-19[4] and a proportion of patients reports only gastrointestinal symptoms [5] . The virus 60 itself is not limited to the lungs but replicates in human enterocytes [6] and is detectable in the 61 patients' fecal samples [1, 7] . GI symptoms in patients with COVID-19 appear to be associated 62 with increased disease severity and complications [ Technical University Munich, Germany. COVID-19 patients, post COVID-19 patients and SC 100 were prospectively recruited between April 2020 to July 2020 (first COVID-19 wave in 101 Germany) and August 2020 to December 2020 (second COVID-19 wave in Germany), whereas 102 the AC group was prospectively recruited between August 2019 and October 2020. Because 103 these were control patients in an intestinal microbiome-only study, saliva was not obtained 104 (Figure 1 A) . Stool, saliva and blood samples were collected at least once per week during the 105 inpatient stay. To ensure follow-up and bio-sample collection after discharge, patients were 106 invited to follow-up visits. SARS-CoV-2 infection was confirmed by quantitative reverse 107 transcription PCR (RT-qPCR), performed on nasopharyngeal swabs. For the post COVID-19 108 patients the first stool sample was collected on average 30 days after the negative PCR. In the 109 AC group, stool samples were collected either before or 6 weeks after bowel preparation for 110 colonoscopy. To characterize the disease activity, laboratory parameters and data regarding 111 REMDESIVIR 15 (13.9) 4 (18.2) 0 (0) 0 (0) CONVALESCENT PLASMA 5 (4.6) 1 (4.5) The explained variation of co-variables was determined by calculating R 2 values and were 153 considered as significant with a p-value ≤0.05. A random forest model was used to classify 154 binary outcome variables based on microbial composition with a 5-fold cross validation by 155 using randomForest from the R package randomForest v4.6-14. To receive a robust and 156 generalizable classification model, the machine-learning algorithm was applied 100-times 157

iteratively. Based on out-of-bag error rates and Gini index, the most important features were 158 selected for each iteration using rfcv from the R package randomForest v4.6-14. Features, which 159 appeared in all 100 random forest models, were considered as classification features for the 160 final model. A generalized linear model for binomial distribution and binary outcome (logit) 161 was generated using the previously selected features. 162

Analysis of the gut microbiota was performed on 251 stool samples (n = 251) from 144 patients 166 (N = 144), of which were 86 COVID-19 patients (n = 150 samples), 21 post COVID-19 patients 167 (n = 60), 11 SC (n = 15) and 26 AC (n = 26) (Figure 1 A) . No bias due to sampling phases was 168 observed allowing a combined analysis of the two COVID-19 waves. 169

Phylogenetic analysis of patient's microbial profile showed no cluster according to SARS-CoV-170 2 status. Nevertheless, some patients were found to have an increased relative abundance of 171

Proteobacteria which was mainly observed with COVID-19 and post COVID-19 samples 172 (Figure 1 C) . The analysis of alpha-diversity revealed a not normally distributed number of 173 observed species and bacterial diversity (Figure 1 B) . The number of observed species was 174 reduced in active COVID-19 (richness 133 ± 90) and post COVID-19 patients (richness 103 ± 175 60) compared to AC (richness 219 ± 68), and bacterial diversity showed a reduced Shannon 176 effective number in SC (Figure 1 D) . 177

Considering only the first sampling time point (T1) per individual revealed that parameters 178 related to patient's health were important effect modifiers (Figure 1 D) . Interestingly, even 179 though the SARS-CoV-2 status alone did not show a clear pattern in the phylogenetic tree, the 180 detection of SARS-CoV-2 in nasopharyngeal swabs significantly influenced the gut microbiota 181 (R 2 = 0.04, p = 0.001), as well as disease related variables, e.g. the disease severity (R 2 = 0.05, 182 p = 0.001). 183 184

Although variables known to influence the microbial composition of the gut such as antibiotics 186 or chemotherapy, appeared to be significant influencing factors (Figure 1 D) , none of the tested 187 variables were confounders within the analysed cohort (Supplementary Table 2 198 were mainly treated at the ICU and received antibiotics (Supplementary Table 4 Table 5 ), which were significantly 214 different between study groups and correlated with markers of inflammation, such as white 215 blood cells counts (WBC), C-reactive protein (CRP) and procalcitonin (PCT) (Figure 2 B) . 216

Here, Clostridium innocuum (zOTU62), Ruthenibacterium lactatiformans (zOTU29), and 217

Alistipes finegoldii (zOTU64) correlated positively with inflammatory markers and continue to 218

show a significantly increased relative abundance or prevalence in patients with a severe disease 219 progression. Negatively correlated zOTUs were significantly decreased in severe and fatal cases 220 of COVID-19 and post COVID-19, such as Faecalibacterium prausnitzii (zOTU20), Blautia 221 luti (zOTU6), Dorea longicatena (zOTU32), Gemmiger formicilis (zOTU30), and Alistipes 222 putredinis (zOTU33). In addition, Fusicatenibacter showed a significantly reduced prevalence 223 in severe cases and was totally absent in patients who died (Figure 2 B) . On the other hand, 224

Parabacteroides significantly increased with a more severe disease (Figure 2 B) . Beta-225 diversity already showed some accumulation of patients with an increased relative abundance 226 of Protobacteria (Figure 1 B) , which was also found to be increased in severe COVID-19 cases 227 (Figure 2 B) . In our study, we demonstrated that the bacterial composition of the gut in patients with COVID-336 19 disease changes with number and type of complications. Thereby, taxa known for protective 337 and immunosuppressive properties were found to be decreased with an increasing complication 338 rate, whereas rather pathogenic taxa were more prevalent. C  O  V  I  D  -1  9  P  O  S  T  C  O  V  I  D  -1 

Depicting SARS-CoV-2 457 faecal viral activity in association with gut microbiota composition in patients with COVID-458 19

Diarrhoea may be 460 underestimated: a missing link in 2019 novel coronavirus

Gastrointestinal 462 Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong 463

Systematic Review and Meta-analysis

COVID-19): A 466 Review

Manifestations and prognosis of 468 gastrointestinal and liver involvement in patients with COVID-19: a systematic review and 469 meta-analysis

SARS-CoV-2 productively infects human gut enterocytes

Characteristics of pediatric 473 SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding

Epidemiological, clinical 476 and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) 477 with gastrointestinal symptoms

Microbiota of Patients With COVID-19 During Time of Hospitalization

Gut microbiota composition 482 reflects disease severity and dysfunctional immune responses in patients with COVID-19

485 Incidence of venous thromboembolism in hospitalized patients with COVID-19

488 Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus 492 Disease 2019 (COVID-19)

Pathophysiology of 494 COVID-19-associated acute kidney injury

Immune determinants of COVID-19 disease presentation and severity

Characteristics of SARS-CoV-2 and COVID-19

Gut microbiota, immunity, and disease: a 500 complex relationship

Linking the Human Gut Microbiome to Inflammatory Cytokine Production Capacity